Israel Englander Cyclerion Therapeutics, Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.43 - $0.9 $658 - $1,378	1,532 Added 4.23%	37,749 $16,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $18.8 $3,831 - $171,493	-9,122 Reduced 20.12%	36,217 $24,000
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $3,624 - $113,750	-6,250 Reduced 12.11%	45,339 $39,000
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $48,699 - $133,665	-103,617 Reduced 66.76%	51,589 $28,000
Q1 2022 May 16, 2022	SELL	$0.96 - $1.78 $90,672 - $168,121	-94,450 Reduced 37.83%	155,206 $172,000
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $80,293 - $153,895	-51,470 Reduced 17.09%	249,656 $429,000
Q3 2021 Nov 15, 2021	SELL	$2.73 - $4.13 $240,007 - $363,088	-87,915 Reduced 22.6%	301,126 $924,000
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.29 $848,109 - $1.67 Million	389,041 New	389,041 $1.52 Million
Q3 2019 Nov 14, 2019	SELL	$8.12 - $14.54 $148,880 - $266,590	-18,335 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $176,016 - $418,954	18,335 New	18,335 $210,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $143M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.